Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ostrow, Sheli L ^a   Simon, Einav ^b   Prinz, Elad ^a   Bick, Tova ^b   Shentzer, Talia ^c   Nagawkar, Sima S ^a   Sabo, Edmond ^a,b   Ben Izhak, Ofer ^a,b   Hershberg, Ruth ^a   Hershkovitz, Dov ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Rambam Health Care Campus ^*  (Israel)

^c Rambam Health Care Campus   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CODON; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADENOCARCINOMA; AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; CODON; COLON TUMOR; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC SELECTION; GENETICS; HUMAN; LUNG TUMOR; MUTATION RATE; PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SMOKING;

ADENOCARCINOMA; AMINO ACID SUBSTITUTION; CODON; COLONIC NEOPLASMS; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MUTATION RATE; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); RISK FACTORS; SELECTION, GENETIC; SMOKING;

EID: 84959109900     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21927     Document Type: Article

References (51)

1. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat Rev Cancer 6, 924-935, doi:10.1038/nrc2013 (2006).
2. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421, doi:10.1038/nature12477 (2013).
3. DeGregori, J. Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? Oncogene 32, 1869-1875, doi:10.1038/onc.2012.281 (2013).
4. Ostrow, S. L., Barshir, R., DeGregori, J., Yeger-Lotem, E. & Hershberg, R. Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet 10, e1004239, doi:10.1371/journal.pgen.1004239 (2014).
5. Watson, I. R., Takahashi, K., Futreal, P. A. & Chin, L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 14, 703-718, doi:10.1038/nrg3539 (2013).
6. Hershberg, R. Mutation-The Engine of Evolution: Studying Mutation and Its Role in the Evolution of Bacteria. Cold Spring Harb Perspect Biol 7, doi:10.1101/cshperspect.a018077 (2015).
7. Vigil, D., Cherfils, J., Rossman, K. L. & Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10, 842-857, doi:10.1038/nrc2960 (2010).
8. Said, R. et al. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 5, 8937-8946 (2014).
9. Cuffe, S. et al. A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. J Thorac Oncol 7, 963-972, doi:10.1097/JTO.0b013e31824fe9e6 (2012).
10. Yoon, H. H. et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20, 3033-3043, doi:10.1158/1078-0432.CCR-13-3140 (2014).
11. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-1634, doi:10.1200/JCO.2007.14.7116 (2008).
12. Burmer, G. C., Rabinovitch, P. S. & Loeb, L. A. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis and pancreatic adenocarcinoma. Environ Health Perspect 93, 27-31 (1991).
13. Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104, 228-239, doi:10.1093/jnci/djr523 (2012).
14. Fiala, O. et al. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet 206, 26-31, doi:10.1016/j.cancergen.2012.12.003 (2013).
15. Imamura, Y. et al. Specific mutations in KRAS codons 12 and 13 and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 18, 4753-4763, doi:10.1158/1078-0432.CCR-11-3210 (2012).
16. De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820, doi:10.1001/jama.2010.1535 (2010).
17. Messner, I. et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol 139, 201-209, doi:10.1007/s00432-012-1319-7 (2013).
18. Metro, G. et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer 78, 81-86, doi:10.1016/j.lungcan.2012.06.005 (2012).
19. Woo, J., Palmisiano, N., Tester, W. & Leighton, J. C., Jr. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 119, 1941-1950, doi:10.1002/cncr.27994 (2013).
20. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551, doi:10.1038/nature12796 (2013).
21. Hershkovitz, D. & Ben-lzhak, O. [Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma]. Harefuah 152, 356-360, 367 (2013).
22. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res 72, 2457-2467, doi:10.1158/0008-5472.CAN-11-2612 (2012).
23. Kawesha, A. et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89, 469-474 (2000).
24. Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V. & Levinson, A. D. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312, 71-75 (1984).
25. Kim, E. Y. et al. KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression. Lung Cancer 85, 299-305, doi:10.1016/j.lungcan.2014.04.012 (2014).
26. Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550, doi:10.1038/nature13385 (2014).
27. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075, doi:10.1038/nature07423 (2008).
28. Takamochi, K., Oh, S. & Suzuki, K. Differences in and mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncol Lett 6, 1207-1212, doi:10.3892/ol.2013.1551 (2013).
29. Tam, I. Y. et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12, 1647-1653, doi:10.1158/1078-0432.CCR-05-1981 (2006).
30. Thu, K. L. et al. Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PLoS One 7, e33003, doi:10.1371/journal.pone.0033003 (2012).
31. Bosetti, C. et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 23, 1880-1888, doi:10.1093/annonc/mdr541 (2012).
32. Zou, L. et al. Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. Eur J Cancer 50, 193-203, doi:10.1016/j.ejca.2013.08.014 (2014).
33. Jiao, L. et al. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34, 55-62, doi:10.1097/01.mpa.0000246665.68869.d4 (2007).
34. Blackford, A. et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 69, 3681-3688, doi:10.1158/0008-5472.CAN-09-0015 (2009).
35. Porta, M. et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res 682, 83-93, doi:10.1016/j.mrrev.2009.07.003 (2009).
36. Krasinskas, A. M., Chiosea, S. I., Pal, T. & Dacic, S. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. Mod Pathol 27, 262-270, doi:10.1038/modpathol.2013.146 (2014).
37. Duell, E. J. Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog 51, 40-52, doi:10.1002/mc.20786 (2012).
38. Pandol, S. et al. Epidemiology, risk factors and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol 27, Suppl 2, 127-134, doi:10.1111/j.1440-1746.2011.07013.x (2012).
39. Kumar, S. et al. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Oncogene 34, 2052-2060, doi:10.1038/onc.2014.154 (2015).
40. Hermann, P. C. et al. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Gastroenterology 147, 1119-1133 e1114, doi:10.1053/j.gastro.2014.08.002 (2014).
41. Edderkaoui, M. & Thrower, E. Smoking and Pancreatic Disease. J Cancer Ther 4, 34-40, doi:10.4236/jct.2013.410A005 (2013).
42. Efrati, E. et al. LNA-based PCR clamping enrichment assay for the identification of KRAS mutations. Cancer Biomark 8, 89-94, doi:10.3233/CBM-2011-0203 (2010).
43. Farber, L. et al. Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. Virchows Arch 459, 487-493, doi:10.1007/s00428-011-1158-y (2011).
44. Nagawkar, S. S. et al. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions. Pancreas, doi:10.1097/MPA.0000000000000562 (2015).
45. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14, 178-192, doi:10.1093/bib/bbs017bbs017 (2013).
46. Robinson, J. T. et al. Integrative genomics viewer. Nat Biotechnol 29, 24-26, doi:10.1038/nbt.1754nbt1754 (2011).
47. Do, H. & Dobrovic, A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem 61, 64-71, doi:10.1373/clinchem.2014.223040 (2015).
48. Spencer, D. H. et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn 15, 623-633, doi:10.1016/j.jmoldx.2013.05.004 (2013).
49. Bragg, L. M., Stone, G., Butler, M. K., Hugenholtz, P. & Tyson, G. W. Shining a light on dark sequencing: characterising errors in Ion Torrent PGM data. PLoS Comput Biol 9, e1003031, doi:10.1371/journal.pcbi.1003031 (2013).
50. Quail, M. A. et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13, 341, doi:10.1186/1471-2164-13-341 (2012).
51. Ross, M. G. et al. Characterizing and measuring bias in sequence data. Genome Biol 14, R51, doi:10.1186/gb-2013-14-5-r51 (2013).